138 results
8-K/A
EX-99.1
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
operations primarily resulted from net loss of $3.0 million and change in fair value of convertible debt of $0.6 million, offset by a non-cash charge … used in operating activities was $1.3 million. The net cash outflow from operations primarily resulted from net loss of $3.4 million, offset
8-K/A
EX-99.2
mxgx7zr6zll8 qq
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
425
EX-99.2
ur9 2ppb7w56
9 Aug 23
Business combination disclosure
4:02pm
8-K
EX-99.2
0nltykrswj
9 Aug 23
Other Events
4:02pm
424B3
3k6 wni8merts
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
ita 8pkx5mog
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
lqg1x34 4u72m6ps9sn1
10 May 23
Registration of securities issued in business combination transactions
9:56pm
S-4
EX-10.23
hs1jk8d4 vsdm4jnj
10 May 23
Registration of securities issued in business combination transactions
9:56pm
8-K
EX-99.1
ump5 wkgc
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
9g8fbljf8boen359
16 May 22
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am